0A4N Stock Overview
A molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.36 |
| 52 Week High | AU$5.12 |
| 52 Week Low | AU$1.92 |
| Beta | 0.42 |
| 1 Month Change | -3.95% |
| 3 Month Change | n/a |
| 1 Year Change | -50.94% |
| 3 Year Change | -87.61% |
| 5 Year Change | n/a |
| Change since IPO | -86.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4N | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 1.9% | 0.2% | 0.4% |
| 1Y | -50.9% | -40.3% | 6.2% |
Return vs Industry: 0A4N underperformed the UK Life Sciences industry which returned -40.3% over the past year.
Return vs Market: 0A4N underperformed the UK Market which returned 6.2% over the past year.
Price Volatility
| 0A4N volatility | |
|---|---|
| 0A4N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A4N's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A4N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 60 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| 0A4N fundamental statistics | |
|---|---|
| Market cap | US$10.62m |
| Earnings (TTM) | -US$8.51m |
| Revenue (TTM) | US$6.86m |
1.5x
P/S Ratio-1.2x
P/E RatioIs 0A4N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4N income statement (TTM) | |
|---|---|
| Revenue | AU$10.24m |
| Cost of Revenue | AU$3.94m |
| Gross Profit | AU$6.30m |
| Other Expenses | AU$19.01m |
| Earnings | -AU$12.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 61.50% |
| Net Profit Margin | -124.08% |
| Debt/Equity Ratio | 0% |
How did 0A4N perform over the long term?
See historical performance and comparison